Amneal Swings To $22 Million Quarterly Loss On Kashiv Costs, Yet Lifts Its 2026 Outlook

Revenue rose 10% to $863 million and adjusted EBITDA hit $207 million, but net debt climbed to $3.07 billion after the Kashiv purchase.

Share
Amneal Swings To $22 Million Quarterly Loss On Kashiv Costs, Yet Lifts Its 2026 Outlook

Amneal Pharmaceuticals, a drugmaker that sells generics, branded medicines and biosimilars, lost $22 million attributable to the company in the third quarter, as costs tied to buying Kashiv BioSciences and a higher tax bill outweighed higher sales. The company still raised its 2026 outlook for revenue and adjusted earnings, and trimmed its operating cash flow forecast, it said Tuesday in an 8-K.

A loss beside a stronger adjusted quarter

The loss works out to $0.06 per diluted share, against net income of $2 million a year earlier. Revenue rose 10% to $863 million from $785 million. The company said non-recurring acquisition and integration costs and a higher tax provision more than offset higher revenue and gross profit. The larger share count after the Kashiv deal also weighed on per-share results.

On adjusted measures the quarter was stronger. Adjusted EBITDA (earnings before interest, taxes, depreciation, amortization and other items the company excludes) rose 30% to $207 million. Adjusted diluted earnings per share rose 53% to $0.26 from $0.17.

Co-CEOs Chirag and Chintu Patel said the Kashiv integration "is proceeding well" and that they see "long-term growth potential in biosimilars."

Generics and branded drugs grow, AvKARE shrinks

Amneal runs three units: Affordable Medicines (retail generics, injectables and biosimilars), Specialty (branded neurology and endocrine drugs) and AvKARE, which distributes to government, retail and institutional customers.

Affordable Medicines revenue grew 19%, driven by biosimilars, women's health patches and new launches. Specialty grew 20%, led by CREXONT, the BREKIYA autoinjector and UNITHROID. AvKARE fell 17%, as expected, because of a non-recurring cardiovascular product launch in the prior year.

Higher targets, more debt, less cash flow

For 2026 the company now expects revenue of $3.15 billion to $3.25 billion, up from $3.10 billion to $3.20 billion. Adjusted EBITDA guidance rises to $800 million to $815 million from $750 million to $780 million, and adjusted EPS to $1.04 to $1.08 from $0.96 to $1.06.

Operating cash flow guidance moves down to $325 million to $375 million from $350 million to $400 million. The company attributed the change to working capital, including higher inventory in key growth areas.

Net debt stood at about $3.07 billion on September 30, up from about $2.41 billion at the end of 2025. Net leverage was 3.9 times adjusted EBITDA, against 3.5 times at year-end. In August the company borrowed an additional $350 million under its term loan to fund part of the Kashiv cash price.

Management discussed the results on a call at 8:30 a.m. ET Tuesday.

Sources